|
Accrued
Expenses, summarized by major category, as of September 30, 2021 and December 31, 2020 consist of the following:
Schedule of Accrued Expenses
| |
|
September 30, 2021 |
|
|
December 31, 2020 |
|
| Payroll and incentives |
|
$ |
944 |
|
|
$ |
1,094 |
|
| General and administrative expenses |
|
|
217 |
|
|
|
280 |
|
| Research and development expenses |
|
|
501 |
|
|
|
778 |
|
| Deferred revenue and other deferred liabilities * |
|
|
1,232 |
|
|
|
643 |
|
| Total |
|
$ |
2,894 |
|
|
$ |
2,795 |
|
| * |
At
September 30, 2021, there was approximately $1,199 thousand deferred liability under the Cystic Fibrosis Foundation (“CFF”)
agreement and approximately $33 thousand in deferred revenue related to the Genentech Agreement. The Company expects to recognize
the deferred revenue and deferred liabilities within the next 12 months. At December 31, 2020, there was an approximately $577 thousand
deferred liability under the CFF Agreement and approximately $67 thousand in deferred revenue related to the Genentech Agreement.
(See Note 9 – Collaboration Agreements, Licenses and Other Research and Development Agreements). |
|